HHCP
PRQR icon

Hilton Head Capital Partners’s ProQR Therapeutics PRQR Stock Holding History

Hilton Head Capital Partners’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Hold
1,404
– – ﹤0.01% 751
2026
Q1 		$2.27K Buy
+1,404
New +$2.3K ﹤0.01% 789

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Hilton Head Capital Partners's PRQR Position: Q2 2026 in Review

Hilton Head Capital Partners held its ProQR Therapeutics (PRQR) position steady in Q2 2026 at 1,404 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #751.

Hilton Head Capital Partners first reported a position in PRQR in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Hilton Head Capital Partners held 1,404 shares of ProQR Therapeutics worth $2.61K as of Q2 2026.
  • Hilton Head Capital Partners left its ProQR Therapeutics share count unchanged in Q2 2026.
  • ProQR Therapeutics made up ﹤0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #751 holding.
  • Hilton Head Capital Partners first reported a position in ProQR Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.